Does CSF copper level in Wilson disease reflect copper accumulation in the brain?

Area of Science:

• Neurology
• Biochemistry
• Medical Diagnostics

Background:

• Wilson disease is a genetic disorder causing copper accumulation.
• Cerebrospinal fluid (CSF) analysis is crucial for diagnosing neurological conditions.
• Understanding copper and ceruloplasmin in CSF aids in Wilson disease management.

Purpose of the Study:

• To investigate the relationship between CSF copper and ceruloplasmin levels and neurological manifestations in Wilson disease.
• To determine if CSF copper or ceruloplasmin can serve as a marker for disease progression and treatment response.

Main Methods:

• Measurement of copper and ceruloplasmin concentrations in CSF samples from Wilson disease patients and controls.
• Correlation analysis of CSF analyte levels with the presence and severity of neurological signs.
• Monitoring of CSF copper levels during D-penicillamine therapy.

Main Results:

• CSF ceruloplasmin levels were consistently lower in Wilson disease patients compared to controls.
• CSF copper levels were normal in patients without neurological signs but significantly elevated in those with neurological involvement.
• CSF copper levels decreased during D-penicillamine treatment, correlating with therapeutic response.

Conclusions:

• CSF copper concentration, not ceruloplasmin, appears to reflect brain copper accumulation in Wilson disease.
• Elevated CSF copper levels in patients with neurological signs suggest a link between brain copper overload and neurological deficits.
• CSF copper levels may serve as a valuable biomarker for monitoring therapeutic efficacy in Wilson disease.